SEC Comment Letter for Hoth Therapeutics, Inc. (HOTH) (CIK 0001711786) (RKTO) — Jun 15, 2023
Hoth Therapeutics, Inc. (HOTH) (CIK 0001711786)
Date: June 15, 2023 · CIK: 0001711786 · Accession: 0000000000-23-006491
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272620
Letter
United States securities and exchange commission logo June 15, 2023 Robb Knie Chief Executive Officer Hoth Therapeutics, Inc. 1 Rockefeller Plaza, Suite 1039 New York, New York 10020 Re:Hoth Therapeutics, Inc. Registration Statement on Form S-3 Filed June 13, 2023 File No. 333-272620 Dear Robb Knie: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nazia J. Khan, Esq.
Show Raw Text
United States securities and exchange commission logo
June 15, 2023
Robb Knie
Chief Executive Officer
Hoth Therapeutics, Inc.
1 Rockefeller Plaza, Suite 1039
New York, New York 10020
Re:Hoth Therapeutics, Inc.
Registration Statement on Form S-3
Filed June 13, 2023
File No. 333-272620
Dear Robb Knie:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Nazia J. Khan, Esq.